Gossamer Bio, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi for a $5M payment to Gossamer (no upfront cost), consolidating full operational control and retaining majority of global economics versus prior 50/50 U.S. profit share. The company received FDA Pre-NDA Type B meeting minutes in mid-June 2026 confirming the FDA views statistical significance and treatment effect as review issues (not filing issues) and plans NDA submission in September 2026, targeting potential Q3 2027 approval decision. Simultaneously, shareholders approved a convertible note exchange reducing $200M of 2027 Notes by 90.5% ($181.1M exchanged for $65.2M of new 2030 Notes plus equity/warrants), cutting total debt by ~$115.9M, leaving $18.9M of 2027 Notes outstanding; cash position stood at $57.0M as of June 30, 2026.
Why this rating
Three material developments: (1) reacquisition captures full economics (~$270.8M market cap benefit from consolidated upside); (2) FDA Pre-NDA feedback de-risks regulatory path; (3) debt reduction of $115.9M (43% of company market cap) materially strengthens balance sheet and extends runway into Q1 2027, significantly improving survival odds for clinical-stage firm.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.